

This is a published notice on the Find a Tender service: <https://www.find-tender.service.gov.uk/Notice/000565-2022>

Tender

Supply of Aseptically Prepared Dose Banded Medicines

HealthTrust Europe LLP (HTE) acting as agent for the University Hospitals of Coventry and Warwickshire NHS Trust (“UHCW”)

F02: Contract notice

Notice identifier: 2022/S 000-000565

Procurement identifier (OCID): ocds-h6vhtk-0308cd

Published 7 January 2022, 10:45pm

Section I: Contracting authority

I.1) Name and addresses

HealthTrust Europe LLP (HTE) acting as agent for the University Hospitals of Coventry and Warwickshire NHS Trust (“UHCW”)

19 George Road

Edgbaston, Birmingham

B15 1NU

Email

Neli.Raleva@htepg.com

Telephone

+44 08458875000

Country

United Kingdom

NUTS code

UK - United Kingdom

Internet address(es)

Main address

<https://healthtrusteurope.bravosolution.co.uk>

I.3) Communication

Access to the procurement documents is restricted. Further information can be obtained at

<https://healthtrusteurope.bravosolution.co.uk>

Additional information can be obtained from the above-mentioned address

Tenders or requests to participate must be submitted electronically via

<https://healthtrusteurope.bravosolution.co.uk>

Tenders or requests to participate must be submitted to the above-mentioned address

I.4) Type of the contracting authority

Ministry or any other national or federal authority

I.5) Main activity

Health

Section II: Object

II.1) Scope of the procurement

II.1.1) Title

Supply of Aseptically Prepared Dose Banded Medicines

Reference number

SF051571

II.1.2) Main CPV code

- 33600000 - Pharmaceutical products

II.1.3) Type of contract

Supplies

II.1.4) Short description

The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists.

The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe's discretion.

II.1.5) Estimated total value

Value excluding VAT: £3,500,000,000

II.1.6) Information about lots

This contract is divided into lots: Yes

Tenders may be submitted for all lots

The contracting authority reserves the right to award contracts combining the following lots or groups of lots:

one or more Lots

II.2) Description

II.2.1) Title

BORTEZOMIB

Lot No

1.1

II.2.2) Additional CPV code(s)

- 33600000 - Pharmaceutical products
- 33692000 - Medical solutions
- 85149000 - Pharmacy services

II.2.3) Place of performance

NUTS codes

- UK - United Kingdom

II.2.4) Description of the procurement

The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists.

The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe's discretion.

II.2.5) Award criteria

Quality criterion - Name: Quality / Weighting: 60%

Price - Weighting: 40%

II.2.6) Estimated value

Value excluding VAT: £100,000,000

II.2.7) Duration of the contract, framework agreement or dynamic purchasing

system

Duration in months

24

This contract is subject to renewal

Yes

Description of renewals

Framework can be extended for up to a period of 24 months at HealthTrust Europe's discretion.

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: No

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

II.2) Description

II.2.1) Title

CARBOPLATIN

Lot No

1.2

II.2.2) Additional CPV code(s)

- 33600000 - Pharmaceutical products
- 33692000 - Medical solutions

- 85149000 - Pharmacy services

II.2.3) Place of performance

NUTS codes

- UK - United Kingdom

II.2.4) Description of the procurement

The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists.

The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe's discretion.

II.2.5) Award criteria

Quality criterion - Name: Quality / Weighting: 60%

Price - Weighting: 40%

II.2.6) Estimated value

Value excluding VAT: £100,000,000

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months

24

This contract is subject to renewal

Yes

Description of renewals

Framework can be extended for up to a period of 24 months at HealthTrust Europe's

discretion.

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: No

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

II.2) Description

II.2.1) Title

CETUXIMAB

Lot No

1.3

II.2.2) Additional CPV code(s)

- 33600000 - Pharmaceutical products
- 33692000 - Medical solutions
- 85149000 - Pharmacy services

II.2.3) Place of performance

NUTS codes

- UK - United Kingdom

II.2.4) Description of the procurement

The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer

presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists.

The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe's discretion.

II.2.5) Award criteria

Quality criterion - Name: Quality / Weighting: 60%

Price - Weighting: 40%

II.2.6) Estimated value

Value excluding VAT: £100,000,000

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months

24

This contract is subject to renewal

Yes

Description of renewals

Framework can be extended for up to a period of 24 months at HealthTrust Europe's discretion.

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: No

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

II.2) Description

II.2.1) Title

CISPLATIN

Lot No

1.4

II.2.2) Additional CPV code(s)

- 33600000 - Pharmaceutical products
- 33692000 - Medical solutions
- 85149000 - Pharmacy services

II.2.3) Place of performance

NUTS codes

- UK - United Kingdom

II.2.4) Description of the procurement

The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists.

The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe's discretion.

II.2.5) Award criteria

Quality criterion - Name: Quality / Weighting: 60%

Price - Weighting: 40%

II.2.6) Estimated value

Value excluding VAT: £100,000,000

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months

24

This contract is subject to renewal

Yes

Description of renewals

Framework can be extended for up to a period of 24 months at HealthTrust Europe's discretion.

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: No

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

II.2) Description

II.2.1) Title

CYCLOPHOSPHAMIDE

Lot No

1.5

II.2.2) Additional CPV code(s)

- 33600000 - Pharmaceutical products
- 33692000 - Medical solutions
- 85149000 - Pharmacy services

II.2.3) Place of performance

NUTS codes

- UK - United Kingdom

II.2.4) Description of the procurement

The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists.

The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe's discretion.

II.2.5) Award criteria

Quality criterion - Name: Quality / Weighting: 60%

Price - Weighting: 40%

II.2.6) Estimated value

Value excluding VAT: £100,000,000

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months

24

This contract is subject to renewal

Yes

Description of renewals

Framework can be extended for up to a period of 24 months at HealthTrust Europe's discretion.

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: No

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

II.2) Description

II.2.1) Title

CYTARABINE

Lot No

1.6

II.2.2) Additional CPV code(s)

- 33600000 - Pharmaceutical products
- 33692000 - Medical solutions
- 85149000 - Pharmacy services

II.2.3) Place of performance

NUTS codes

- UK - United Kingdom

II.2.4) Description of the procurement

The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists.

The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe's discretion.

II.2.5) Award criteria

Quality criterion - Name: Quality / Weighting: 60%

Price - Weighting: 40%

II.2.6) Estimated value

Value excluding VAT: £100,000,000

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months

24

This contract is subject to renewal

Yes

Description of renewals

Framework can be extended for up to a period of 24 months at HealthTrust Europe's discretion.

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: No

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

II.2) Description

II.2.1) Title

DEFERRIOXAMINE

Lot No

1.7

II.2.2) Additional CPV code(s)

- 33600000 - Pharmaceutical products
- 33692000 - Medical solutions
- 85149000 - Pharmacy services

II.2.3) Place of performance

NUTS codes

- UK - United Kingdom

II.2.4) Description of the procurement

The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists.

The duration of the framework agreement will be two (2) years initial period with the option

of extending for up to twenty four (24) months, at HealthTrust Europe's discretion.

II.2.5) Award criteria

Quality criterion - Name: Quality / Weighting: 60%

Price - Weighting: 40%

II.2.6) Estimated value

Value excluding VAT: £100,000,000

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months

24

This contract is subject to renewal

Yes

Description of renewals

Framework can be extended for up to a period of 24 months at HealthTrust Europe's discretion.

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: No

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

II.2) Description

II.2.1) Title

DOCETAXEL

Lot No

1.8

II.2.2) Additional CPV code(s)

- 33600000 - Pharmaceutical products
- 33692000 - Medical solutions
- 85149000 - Pharmacy services

II.2.3) Place of performance

NUTS codes

- UK - United Kingdom

II.2.4) Description of the procurement

The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists.

The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe's discretion.

II.2.5) Award criteria

Quality criterion - Name: Quality / Weighting: 60%

Price - Weighting: 40%

II.2.6) Estimated value

Value excluding VAT: £100,000,000

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months

24

This contract is subject to renewal

Yes

Description of renewals

Framework can be extended for up to a period of 24 months at HealthTrust Europe's discretion.

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: No

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

II.2) Description

II.2.1) Title

DOXORUBICIN

Lot No

1.9

II.2.2) Additional CPV code(s)

- 33600000 - Pharmaceutical products

- 33692000 - Medical solutions
- 85149000 - Pharmacy services

II.2.3) Place of performance

NUTS codes

- UK - United Kingdom

II.2.4) Description of the procurement

The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists.

The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe's discretion.

II.2.5) Award criteria

Quality criterion - Name: Quality / Weighting: 60%

Price - Weighting: 40%

II.2.6) Estimated value

Value excluding VAT: £100,000,000

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months

24

This contract is subject to renewal

Yes

Description of renewals

Framework can be extended for up to a period of 24 months at HealthTrust Europe's discretion.

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: No

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

II.2) Description

II.2.1) Title

EPIRUBICIN

Lot No

1.10

II.2.2) Additional CPV code(s)

- 33600000 - Pharmaceutical products
- 33692000 - Medical solutions
- 85149000 - Pharmacy services

II.2.3) Place of performance

NUTS codes

- UK - United Kingdom

II.2.4) Description of the procurement

The Tender is to establish a framework agreement for the supply of a range of aseptically

prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists.

The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe's discretion.

II.2.5) Award criteria

Quality criterion - Name: Quality / Weighting: 60%

Price - Weighting: 40%

II.2.6) Estimated value

Value excluding VAT: £100,000,000

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months

24

This contract is subject to renewal

Yes

Description of renewals

Framework can be extended for up to a period of 24 months at HealthTrust Europe's discretion.

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: No

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

II.2) Description

II.2.1) Title

FLUOROURACIL

Lot No

1.11

II.2.2) Additional CPV code(s)

- 33600000 - Pharmaceutical products
- 33692000 - Medical solutions
- 85149000 - Pharmacy services

II.2.3) Place of performance

NUTS codes

- UK - United Kingdom

II.2.4) Description of the procurement

The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists.

The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe's discretion.

II.2.5) Award criteria

Quality criterion - Name: Quality / Weighting: 60%

Price - Weighting: 40%

II.2.6) Estimated value

Value excluding VAT: £100,000,000

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months

24

This contract is subject to renewal

Yes

Description of renewals

Framework can be extended for up to a period of 24 months at HealthTrust Europe's discretion.

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: No

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

II.2) Description

II.2.1) Title

GANCICLOVIR

Lot No

1.12

II.2.2) Additional CPV code(s)

- 33600000 - Pharmaceutical products
- 33692000 - Medical solutions
- 85149000 - Pharmacy services

II.2.3) Place of performance

NUTS codes

- UK - United Kingdom

II.2.4) Description of the procurement

The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists.

The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe's discretion.

II.2.5) Award criteria

Quality criterion - Name: Quality / Weighting: 60%

Price - Weighting: 40%

II.2.6) Estimated value

Value excluding VAT: £100,000,000

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months

24

This contract is subject to renewal

Yes

Description of renewals

Framework can be extended for up to a period of 24 months at HealthTrust Europe's discretion.

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: No

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

II.2) Description

II.2.1) Title

GEMCITABINE

Lot No

1.13

II.2.2) Additional CPV code(s)

- 33600000 - Pharmaceutical products
- 33692000 - Medical solutions
- 85149000 - Pharmacy services

II.2.3) Place of performance

NUTS codes

- UK - United Kingdom

II.2.4) Description of the procurement

The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists.

The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe's discretion.

II.2.5) Award criteria

Quality criterion - Name: Quality / Weighting: 60%

Price - Weighting: 40%

II.2.6) Estimated value

Value excluding VAT: £100,000,000

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months

24

This contract is subject to renewal

Yes

Description of renewals

Framework can be extended for up to a period of 24 months at HealthTrust Europe's discretion.

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: No

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

II.2) Description

II.2.1) Title

INFLIXIMAB

Lot No

1.14

II.2.2) Additional CPV code(s)

- 33600000 - Pharmaceutical products
- 33692000 - Medical solutions
- 85149000 - Pharmacy services

II.2.3) Place of performance

NUTS codes

- UK - United Kingdom

II.2.4) Description of the procurement

The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists.

The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe's discretion.

II.2.5) Award criteria

Quality criterion - Name: Quality / Weighting: 60%

Price - Weighting: 40%

II.2.6) Estimated value

Value excluding VAT: £100,000,000

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months

24

This contract is subject to renewal

Yes

Description of renewals

Framework can be extended for up to a period of 24 months at HealthTrust Europe's discretion.

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: No

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

II.2) Description

II.2.1) Title

IRINOTECAN

Lot No

1.15

II.2.2) Additional CPV code(s)

- 33600000 - Pharmaceutical products
- 33692000 - Medical solutions
- 85149000 - Pharmacy services

II.2.3) Place of performance

NUTS codes

- UK - United Kingdom

II.2.4) Description of the procurement

The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists.

The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe's discretion.

II.2.5) Award criteria

Quality criterion - Name: Quality / Weighting: 60%

Price - Weighting: 40%

II.2.6) Estimated value

Value excluding VAT: £100,000,000

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months

24

This contract is subject to renewal

Yes

Description of renewals

Framework can be extended for up to a period of 24 months at HealthTrust Europe's discretion.

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: No

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

II.2) Description

II.2.1) Title

METHOTREXATE

Lot No

1.16

II.2.2) Additional CPV code(s)

- 33600000 - Pharmaceutical products

- 33692000 - Medical solutions
- 85149000 - Pharmacy services

II.2.3) Place of performance

NUTS codes

- UK - United Kingdom

II.2.4) Description of the procurement

The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists.

The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe's discretion.

II.2.5) Award criteria

Quality criterion - Name: Quality / Weighting: 60%

Price - Weighting: 40%

II.2.6) Estimated value

Value excluding VAT: £100,000,000

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months

24

This contract is subject to renewal

Yes

Description of renewals

Framework can be extended for up to a period of 24 months at HealthTrust Europe's discretion.

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: No

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

II.2) Description

II.2.1) Title

NIVOLUMAB

Lot No

1.17

II.2.2) Additional CPV code(s)

- 33600000 - Pharmaceutical products
- 33692000 - Medical solutions
- 85149000 - Pharmacy services

II.2.3) Place of performance

NUTS codes

- UK - United Kingdom

II.2.4) Description of the procurement

The Tender is to establish a framework agreement for the supply of a range of aseptically

prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists.

The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe's discretion.

II.2.5) Award criteria

Quality criterion - Name: Quality / Weighting: 60%

Price - Weighting: 40%

II.2.6) Estimated value

Value excluding VAT: £100,000,000

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months

24

This contract is subject to renewal

Yes

Description of renewals

Framework can be extended for up to a period of 24 months at HealthTrust Europe's discretion.

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: No

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

II.2) Description

II.2.1) Title

OXALIPLATIN

Lot No

1.18

II.2.2) Additional CPV code(s)

- 33600000 - Pharmaceutical products
- 33692000 - Medical solutions
- 85149000 - Pharmacy services

II.2.3) Place of performance

NUTS codes

- UK - United Kingdom

II.2.4) Description of the procurement

The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists.

The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe's discretion.

II.2.5) Award criteria

Quality criterion - Name: Quality / Weighting: 60%

Price - Weighting: 40%

II.2.6) Estimated value

Value excluding VAT: £100,000,000

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months

24

This contract is subject to renewal

Yes

Description of renewals

Framework can be extended for up to a period of 24 months at HealthTrust Europe's discretion.

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: No

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

II.2) Description

II.2.1) Title

PACLITAXEL

Lot No

1.19

II.2.2) Additional CPV code(s)

- 33600000 - Pharmaceutical products
- 33692000 - Medical solutions
- 85149000 - Pharmacy services

II.2.3) Place of performance

NUTS codes

- UK - United Kingdom

II.2.4) Description of the procurement

The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists.

The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe's discretion.

II.2.5) Award criteria

Quality criterion - Name: Quality / Weighting: 60%

Price - Weighting: 40%

II.2.6) Estimated value

Value excluding VAT: £100,000,000

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months

24

This contract is subject to renewal

Yes

Description of renewals

Framework can be extended for up to a period of 24 months at HealthTrust Europe's discretion.

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: No

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

II.2) Description

II.2.1) Title

PEMBROLIZUMAB

Lot No

1.20

II.2.2) Additional CPV code(s)

- 33600000 - Pharmaceutical products
- 33692000 - Medical solutions
- 85149000 - Pharmacy services

II.2.3) Place of performance

NUTS codes

- UK - United Kingdom

II.2.4) Description of the procurement

The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists.

The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe's discretion.

II.2.5) Award criteria

Quality criterion - Name: Quality / Weighting: 60%

Price - Weighting: 40%

II.2.6) Estimated value

Value excluding VAT: £100,000,000

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months

24

This contract is subject to renewal

Yes

Description of renewals

Framework can be extended for up to a period of 24 months at HealthTrust Europe's discretion.

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: No

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

II.2) Description

II.2.1) Title

PERTUZUMAB

Lot No

1.21

II.2.2) Additional CPV code(s)

- 33600000 - Pharmaceutical products
- 33692000 - Medical solutions
- 85149000 - Pharmacy services

II.2.3) Place of performance

NUTS codes

- UK - United Kingdom

II.2.4) Description of the procurement

The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists.

The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe's discretion.

II.2.5) Award criteria

Quality criterion - Name: Quality / Weighting: 60%

Price - Weighting: 40%

II.2.6) Estimated value

Value excluding VAT: £100,000,000

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months

24

This contract is subject to renewal

Yes

Description of renewals

Framework can be extended for up to a period of 24 months at HealthTrust Europe's discretion.

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: No

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

II.2) Description

II.2.1) Title

RITUXIMAB

Lot No

1.22

II.2.2) Additional CPV code(s)

- 33600000 - Pharmaceutical products
- 33692000 - Medical solutions
- 85149000 - Pharmacy services

II.2.3) Place of performance

NUTS codes

- UK - United Kingdom

II.2.4) Description of the procurement

The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists.

The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe's discretion.

II.2.5) Award criteria

Quality criterion - Name: Quality / Weighting: 60%

Price - Weighting: 40%

II.2.6) Estimated value

Value excluding VAT: £100,000,000

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months

24

This contract is subject to renewal

Yes

Description of renewals

Framework can be extended for up to a period of 24 months at HealthTrust Europe's discretion.

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: No

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

II.2) Description

II.2.1) Title

TRASTUZUMAB SC

Lot No

1.23

II.2.2) Additional CPV code(s)

- 33600000 - Pharmaceutical products

- 33692000 - Medical solutions
- 85149000 - Pharmacy services

II.2.3) Place of performance

NUTS codes

- UK - United Kingdom

II.2.4) Description of the procurement

The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists.

The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe's discretion.

II.2.5) Award criteria

Quality criterion - Name: Quality / Weighting: 60%

Price - Weighting: 40%

II.2.6) Estimated value

Value excluding VAT: £100,000,000

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months

24

This contract is subject to renewal

Yes

Description of renewals

Framework can be extended for up to a period of 24 months at HealthTrust Europe's discretion.

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: No

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

II.2) Description

II.2.1) Title

TRASTUZUMAB IV

Lot No

1.24

II.2.2) Additional CPV code(s)

- 33600000 - Pharmaceutical products
- 33692000 - Medical solutions
- 85149000 - Pharmacy services

II.2.3) Place of performance

NUTS codes

- UK - United Kingdom

II.2.4) Description of the procurement

The Tender is to establish a framework agreement for the supply of a range of aseptically

prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists.

The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe's discretion.

II.2.5) Award criteria

Quality criterion - Name: Quality / Weighting: 60%

Price - Weighting: 40%

II.2.6) Estimated value

Value excluding VAT: £100,000,000

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months

24

This contract is subject to renewal

Yes

Description of renewals

Framework can be extended for up to a period of 24 months at HealthTrust Europe's discretion.

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: No

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

II.2) Description

II.2.1) Title

VINCRIStINE

Lot No

1.25

II.2.2) Additional CPV code(s)

- 33600000 - Pharmaceutical products
- 33692000 - Medical solutions
- 85149000 - Pharmacy services

II.2.3) Place of performance

NUTS codes

- UK - United Kingdom

II.2.4) Description of the procurement

The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists.

The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe's discretion.

II.2.5) Award criteria

Quality criterion - Name: Quality / Weighting: 60%

Price - Weighting: 40%

II.2.6) Estimated value

Value excluding VAT: £100,000,000

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months

24

This contract is subject to renewal

Yes

Description of renewals

Framework can be extended for up to a period of 24 months at HealthTrust Europe's discretion.

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: No

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

II.2) Description

II.2.1) Title

Aseptically Prepared Dose Banded Medicines

Lot No

2

II.2.2) Additional CPV code(s)

- 33600000 - Pharmaceutical products
- 33680000 - Pharmaceutical articles
- 85149000 - Pharmacy services

II.2.3) Place of performance

NUTS codes

- UK - United Kingdom

II.2.4) Description of the procurement

The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists.

The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe's discretion.

II.2.5) Award criteria

Quality criterion - Name: Quality / Weighting: 60%

Price - Weighting: 40%

II.2.6) Estimated value

Value excluding VAT: £500,000,000

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months

24

This contract is subject to renewal

Yes

Description of renewals

Framework can be extended for up to a period of 24 months at HealthTrust Europe's discretion.

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: No

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

II.2) Description

II.2.1) Title

CIVAS

Lot No

3

II.2.2) Additional CPV code(s)

- 33600000 - Pharmaceutical products
- 33680000 - Pharmaceutical articles
- 85149000 - Pharmacy services

II.2.3) Place of performance

NUTS codes

- UK - United Kingdom

II.2.4) Description of the procurement

The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists.

The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe's discretion.

II.2.5) Award criteria

Quality criterion - Name: Quality / Weighting: 60%

Price - Weighting: 40%

II.2.6) Estimated value

Value excluding VAT: £200,000,000

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months

24

This contract is subject to renewal

Yes

Description of renewals

Framework can be extended for up to a period of 24 months at HealthTrust Europe's discretion.

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: No

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

II.2) Description

II.2.1) Title

Patient Specific Chemotherapy

Lot No

4

II.2.2) Additional CPV code(s)

- 33600000 - Pharmaceutical products
- 33680000 - Pharmaceutical articles
- 85149000 - Pharmacy services

II.2.3) Place of performance

NUTS codes

- UK - United Kingdom

II.2.4) Description of the procurement

The Tender is to establish a framework agreement for the supply of a range of aseptically prepared patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists.

The duration of the framework agreement will be two (2) years initial period with the option

of extending for up to twenty four (24) months, at HealthTrust Europe's discretion.

II.2.5) Award criteria

Quality criterion - Name: Quality / Weighting: 60%

Price - Weighting: 40%

II.2.6) Estimated value

Value excluding VAT: £300,000,000

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months

24

This contract is subject to renewal

Yes

Description of renewals

Framework can be extended for up to a period of 24 months at HealthTrust Europe's discretion.

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: No

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

Section IV. Procedure

IV.1) Description

IV.1.1) Type of procedure

Open procedure

IV.1.3) Information about a framework agreement or a dynamic purchasing system

The procurement involves the establishment of a framework agreement

Framework agreement with several operators

IV.1.8) Information about the Government Procurement Agreement (GPA)

The procurement is covered by the Government Procurement Agreement: Yes

IV.2) Administrative information

IV.2.2) Time limit for receipt of tenders or requests to participate

Date

14 February 2022

Local time

12:00pm

IV.2.4) Languages in which tenders or requests to participate may be submitted

English

IV.2.7) Conditions for opening of tenders

Date

14 February 2022

Local time

12:01pm

Section VI. Complementary information

VI.1) Information about recurrence

This is a recurrent procurement: No

VI.3) Additional information

TERMS AND CONDITIONS / ACTIVITY BASED INCOME (ABI)

The terms and conditions of this Framework Agreement is appended to the ITT. These terms include provisions requiring the payment by the supplier of an ABI management charge in consideration of the award of this Framework Agreement, the management and administration by HTE of the overall contract structure and associated documentation, as well as the requirement to submit regular management information to HTE.

SUBMISSION OF EXPRESSIONS OF INTEREST AND PROCUREMENT INFORMATION.

This exercise will be conducted on the HTE Bravo portal. Candidates wishing to be considered must register expressions of interest as follows:

Register on the HTE portal at <https://healthtrusteurope.bravosolution.co.uk>. Login to the portal with username/password. Click the SQs/ITTs Open to All Suppliers link. These are the SQs/ITTs open to any registered supplier. Click on the relevant SQs/ITT to access the content. Click the Express Interest button at the top of the page. This will move the SQs/ITT into your My SQs/My ITTs page. You can access any attachments by clicking Buyer Attachments in the SQs/ITT Details box. Follow the onscreen instructions to complete the SQs/ITT. Submit your reply using the Submit Response button at the top of the page. If you

require any further advice, contact the Bravo e-Tendering Help Desk at help@bravosolution.co.uk.

Sid4Gov

HTE utilises the sid4gov supplier information database. Candidates should register on sid4gov at <https://sid4gov.cabinetoffice.gov.uk/organisation/register> and submit their sid4gov company profile for publication on the database. Candidates already registered on sid4gov must ensure information is up to date.

Where access to sid4gov is unavailable, please contact the sid4gov helpdesk at sid4gov@gps.gsi.gov.uk.

Please note that sid4gov does not prepopulate any fields of the SQ on HTE's Bravo Portal. Candidates must complete the Qualification & Technical envelopes of the SQ on Bravo in full.

VI.4) Procedures for review

VI.4.1) Review body

Legal Department

19 George Road

Birmingham

B15 1NU

Country

United Kingdom